Beyond germline mutations, findings from a small series of longitudinal samples from the same patient suggest that, at least for BRCA1 and BRCA2, somatic HRR mutations are usually detectable in primary tumours in comparison with other genomic events, such as AR alterations, that emerge later in response to treatment‐selective pressure [17, 22]. The gene discussed is BRCA2; the disease is neoplasm.